Pfizer Inc Stock Performance
| PFE Stock | USD 26.30 0.01 0.04% |
Pfizer has a performance score of 4 on a scale of 0 to 100. The company holds a Beta of 0.18, which implies not very significant fluctuations relative to the market. As returns on the market increase, Pfizer's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pfizer is expected to be smaller as well. Pfizer Inc right now holds a risk of 1.21%. Please check Pfizer Inc total risk alpha, expected short fall, period momentum indicator, as well as the relationship between the value at risk and rate of daily change , to decide if Pfizer Inc will be following its historical price patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Pfizer Inc are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound technical and fundamental indicators, Pfizer is not utilizing all of its potentials. The newest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.79 | Five Day Return 1.92 | Year To Date Return (1.33) | Ten Year Return (19.44) | All Time Return 6 K |
Forward Dividend Yield 0.066 | Payout Ratio | Last Split Factor 1054:1000 | Forward Dividend Rate 1.72 | Dividend Date 2025-03-07 |
1 | Disposition of 12038 shares by Boshoff Christoffel of Pfizer at 26.52 subject to Rule 16b-3 | 01/31/2025 |
2 | Altrius Capital Management Inc Raises Holdings in Pfizer Inc. | 02/28/2025 |
3 | Why Moderna Stock Is Rallying Today | 03/05/2025 |
| Pfizer dividend paid on 7th of March 2025 | 03/07/2025 |
4 | BioNTech posts 721M loss in 2024 due to low demand for COVID-19 vaccines | 03/10/2025 |
5 | ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor and highly potent caps... | 03/11/2025 |
6 | ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP | 03/12/2025 |
7 | Pfizer Stock Moves -0.43 percent What You Should Know | 03/13/2025 |
8 | Pfizer Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits | 03/14/2025 |
| Begin Period Cash Flow | 2.9 B |
Pfizer |
Pfizer Relative Risk vs. Return Landscape
If you would invest 2,535 in Pfizer Inc on December 19, 2024 and sell it today you would earn a total of 96.00 from holding Pfizer Inc or generate 3.79% return on investment over 90 days. Pfizer Inc is generating 0.0702% of daily returns assuming volatility of 1.207% on return distribution over 90 days investment horizon. In other words, 10% of stocks are less volatile than Pfizer, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Pfizer Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pfizer's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pfizer Inc, and traders can use it to determine the average amount a Pfizer's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0581
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | PFE | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.21 actual daily | 10 90% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Pfizer is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pfizer by adding it to a well-diversified portfolio.
Pfizer Fundamentals Growth
Pfizer Stock prices reflect investors' perceptions of the future prospects and financial health of Pfizer, and Pfizer fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pfizer Stock performance.
| Return On Equity | 0.0906 | ||||
| Return On Asset | 0.0464 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 190.91 B | ||||
| Shares Outstanding | 5.67 B | ||||
| Price To Earning | 9.48 X | ||||
| Price To Book | 1.68 X | ||||
| Price To Sales | 2.32 X | ||||
| Revenue | 63.63 B | ||||
| Gross Profit | 47.21 B | ||||
| EBITDA | 18.13 B | ||||
| Net Income | 8.05 B | ||||
| Cash And Equivalents | 2.85 B | ||||
| Cash Per Share | 6.44 X | ||||
| Total Debt | 63.65 B | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 1.59 X | ||||
| Book Value Per Share | 15.56 X | ||||
| Cash Flow From Operations | 12.74 B | ||||
| Earnings Per Share | 1.41 X | ||||
| Market Capitalization | 147.74 B | ||||
| Total Asset | 213.4 B | ||||
| Retained Earnings | 116.72 B | ||||
| Working Capital | 7.36 B | ||||
| Current Asset | 43.8 B | ||||
| Current Liabilities | 29.4 B | ||||
About Pfizer Performance
By analyzing Pfizer's fundamental ratios, stakeholders can gain valuable insights into Pfizer's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pfizer has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pfizer has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 241.21 | 270.47 | |
| Return On Tangible Assets | 0.09 | 0.11 | |
| Return On Capital Employed | 0.09 | 0.08 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.09 | 0.09 |
Things to note about Pfizer Inc performance evaluation
Checking the ongoing alerts about Pfizer for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pfizer Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 67.0% of the company shares are owned by institutional investors | |
| On 7th of March 2025 Pfizer paid $ 0.43 per share dividend to its current shareholders | |
| Latest headline from simplywall.st: Pfizer Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits |
- Analyzing Pfizer's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pfizer's stock is overvalued or undervalued compared to its peers.
- Examining Pfizer's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pfizer's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pfizer's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pfizer's stock. These opinions can provide insight into Pfizer's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |